Blue Hawk Ventures

Molecular Pharmacology (USA) Limited, formerly known as Blue Hawk Ventures, is a biotechnology company specializing in the development of peptide-based therapeutics for pain and inflammation. The company utilizes its proprietary Tripeptofen platform to derive therapeutic oligopeptides from natural protein sources, targeting key mediators in the inflammatory cascade such as TNF-alpha and COX-2. Its lead clinical candidate, MPL-TL100, is a topical formulation being evaluated for the treatment of lateral epicondylitis (tennis elbow) and other musculoskeletal pain conditions. Originally incorporated as a mineral exploration company in 2002, the firm underwent a strategic pivot to life sciences in 2005 following its acquisition of the Tripeptofen technology. Molecular Pharmacology (USA) operates as a subsidiary of the Australian-based Pharmanet Group Limited and is focused on bringing a new class of non-opioid analgesics to the global market.